Saturday, September 5, 2026

AI Economics

2 articles

Goldman Forecasts 7-Point Big Tech ROE Drop as AI Capex Fails to Deliver Returns

Goldman Forecasts 7-Point Big Tech ROE Drop as AI Capex Fails to Deliver Returns

Goldman Sachs has forecast a 7 percentage point decline in Big Tech return on equity, citing AI capital expenditure that has not yet translated to measurable business returns. The bank published an AI spending and profitability report alongside the bearish ROE forecast, signaling institutional concern about the current AI investment cycle. Markets are now pricing in near-term derating of AI infrastructure stocks as margin compression outpaces revenue uplift.

LM Salvado
Nobel Economist Says AI Will Deliver a 'Small' Productivity Boost—Not the Revolution Markets Are Pricing

Nobel Economist Says AI Will Deliver a 'Small' Productivity Boost—Not the Revolution Markets Are Pricing

Nobel laureate Daron Acemoglu argues AI will give only a modest productivity boost and won't eliminate human work, colliding with equity valuations built on transformative automation assumptions. The disconnect sharpens as CPI runs at 3.8%, gasoline costs rise $857 per household, and consumer sentiment deteriorates among the income cohorts most likely to buy AI tools.

LM Salvado
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com